Tonix Pharmaceuticals to Present Tonmya Data at 2026 AAPM PainConnect Annual Meeting

Tonix Pharmaceuticals Holding Corp. announced that a poster on Tonmya, investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine. The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the company will share data related to its investigational therapy as part of the scientific program. This presentation matters because it represents an opportunity for the medical community to evaluate new clinical data on a treatment that addresses significant unmet needs in pain management and central nervous system disorders.

Tonmya is the company's recently approved flagship medicine and represents the first new treatment for fibromyalgia in more than 15 years. The importance of this development cannot be overstated, as fibromyalgia affects millions of patients worldwide who have had limited treatment options for nearly two decades. The presentation at the AAPM meeting will provide pain medicine specialists with crucial information about this novel therapeutic approach. Additional information about the company's developments is available in its newsroom at https://ibn.fm/TNXP.

Beyond its approved indication for fibromyalgia, Tonix is maximizing the science behind Tonmya in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. This expansion into additional central nervous system conditions demonstrates the compound's broad therapeutic potential and the company's strategic approach to addressing multiple areas of high unmet medical need. The presentation at the PainConnect meeting will likely include data supporting these expanded applications, which could significantly impact treatment paradigms for these challenging conditions.

The company's central nervous system portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Additionally, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These developments highlight Tonix's comprehensive approach to biotechnology innovation across multiple therapeutic areas. It is important to note that the company's product development candidates are investigational new drugs or biologics whose efficacy and safety have not been established and have not been approved for any indication beyond Tonmya's current approval.

The 2026 PainConnect Annual Meeting presentation represents a significant milestone for Tonix Pharmaceuticals as it seeks to establish Tonmya as a transformative treatment in pain medicine and psychiatry. The data presentation will provide clinicians and researchers with valuable insights into the mechanism of action, efficacy, and safety profile of this novel sublingual formulation. As the medical community continues to seek improved treatments for chronic pain conditions and related central nervous system disorders, presentations like this one at major scientific meetings play a crucial role in advancing therapeutic options for patients who have limited alternatives. The full press release containing additional details about this announcement can be viewed at https://ibn.fm/kwTPM.